{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/69d9381eaf4db69e0df8e553/6aa8653e1563582c05f5b08b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"FDA Regulation and the Dynamic Nature of AI ","description":"<p>Dr. Brian Miller has seen medical technology regulation from every side — as a hospitalist, a former FDA official, and now an associate professor at Johns Hopkins University, where he leads a research group on market-driven approaches to FDA regulation and Medicare payment policy.&nbsp;In this episode, Chip talks with Miller about what happens when the FDA applies its 1976 medical device framework to AI — a technology that learns and changes.</p><p><br></p><p>Miller's argument may surprise you: the manual system of medicine we have today is already less safe and less consistent than most people assume. What keeps him up at night isn't the speed of AI — it's the risk that fear-driven regulation will cost us the opportunities AI offers. The conversation was recorded shortly before the FDA released a discussion paper outlining possible regulatory approaches and inviting stakeholder feedback. Chip weighs in on the paper at the end of the episode.&nbsp;</p>","author_name":"KFF"}